Clinical Trial Update: TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating the combination of transarterial chemoembolization (TACE) with lenvatinib for unresectable hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN